HOME >> BIOLOGY >> NEWS
Continued Prophylactic Treatment Of P. Marneffei Can Prevent Relapse

A large number of patients in Thailand who are infected with the Human Immunodeficiency Virus (HIV) have become ill from a previously very rare fungus called Penicillium Marneffei. Giving prophylactic itraconazole, an anti-fungal drug, to patients who have been treated for P. Marneffei, a potentially fatal fungal infection, can prevent a relapse of the infection. In a study of patients with HIV infection who responded to primary treatment for Penicillium Marneffei, researchers from the Johns Hopkins School of Public Health and Chiang Mai University in Thailand successfully administered itraconazole and prevented the recurrence of P. Marneffei. The study was published in the December 10, 1998 issue of The New England Journal of Medicine.

Kenrad Nelson, MD, professor, Epidemiology, Johns Hopkins School of Public Health said, "The relapse rate for P. Marneffei is about 50 percent in those patients without continued preventive treatment. We wanted to find a preventive treatment that was highly effective and well tolerated. We didn't expect the drug would work as well as it did." Dr. Nelson's team looked at 71 HIV- positive patients in Thailand who had received treatment for P. Marneffei. Half of them received itraconazole and half received a placebo. Twenty of those in the placebo group, more than half, had a relapse of P. Marneffei during the course of the study. None of those treated with itraconazole had a relapse. The median time to relapse was 24 weeks.

In northern Thailand, P. Marneffei is the third most common opportunistic infection in HIV patients. The infection causes weight loss, fever, anemia, and skin lesions. It has a 20% fatality rate even with appropriate treatment but is 100% fatal if not diagnosed and treated. Preventing relapse is highly preferable to treatment since some relapses can not be treated successfully. Dr. Nelson said, "This regimen should be the standard of care for patients with AI
'"/>

Contact: Kathi Moore
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
10-Dec-1998


Page: 1 2

Related biology news :

1. St. Petersburg/New Haven Partnership for HIV/AIDS Care, Treatment and Support launched
2. Treatment stimulates growth and regeneration of injured adult skeletal muscle
3. Treatment of lupus in mice may point the way to human treatment
4. Treatment in mice proves effective against Duchenne muscular dystrophy
5. Treatment protects mouse ovaries from radiation therapy
6. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
7. Treatment restores normal heart rhythm in patients
8. Researchers Develop New Treatment For Hepatitis B And C As Nation Anticipates Surge In Number Of Cases
9. Researchers: Exciting Discovery Might Improve Cancer Treatment
10. Coffee Without Addiction, Possible New Treatment For Osteoporosis, Wrinkle-Free Cotton, And More
11. Scientists Discover Molecular Trigger Of Mucus Production, Suggesting First Treatment For Deadly Bronchitis, Other Diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Biology News(10 mins):
(Date:9/17/2017)... ... 17, 2017 , ... GeneOne Life Science, Inc. announces that ... Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study ... The study in Korea represents the second clinical trial for GLS-5300. , ...
(Date:9/14/2017)... ... September 14, 2017 , ... Boston Strategic ... experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to provide ... 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. ...
(Date:9/13/2017)... ... 13, 2017 , ... AMRI, a global contract research, development ... and quality of life for more than 25 years, today announced that John ... the International Standards Organization/Technical Committee 194: Biological and Clinical Evaluation of Medical ...
(Date:9/12/2017)... (PRWEB) , ... September 12, 2017 , ... It wasn’t ... months, it has been hot, hot, hot, as Lajollacooks4u has had a record-breaking number ... , Guests came from far and wide to celebrate company outings, family get-togethers, anniversaries ...
Breaking Biology Technology:
Cached News: